Stock Comparison

LLY vs ZVRA

Eli Lilly and Co vs Zevra Therapeutics Inc

The Verdict

ZVRA takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

ZVRA

Zevra Therapeutics Inc

7.5

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$589M

52.6

P/E Ratio

7.1

N/A

Profit Margin

78.2%

N/A

Return on Equity

74.6%

N/A

Debt-to-Equity

0.4

Moderate

Overall Risk

Moderate

0.5

DVR Score

7.5

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

ZVRA7.5/10

Score Change Explanation: The previous analysis (2026-03-30, score 9.2/10) heavily weighted the 'significantly de-risked' future approval of Arimoclomol (Niemann-Pick Type C) with a mid-2026 PDUFA date and a 'strong pipeline'. However, updated real-time intelligence reveals material shifts: 1) Zevra has pivoted to a 'single-asset (MIPLYFFA) focus' by selling its SDX portfolio, significantly reduci...

Full ZVRA Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.